NuCana, a UK biotech developing enhanced chemotherapies for resistant tumors, filed on Friday with the SEC to raise up to $115 million in an initial public offering.
The Edinburgh, United Kingdom-based company was founded in 2008 and plans to list on the Nasdaq under the symbol NCNA. NuCana filed confidentially on June 26, 2017. Citi, Jefferies and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
